3006.93.60.00/Blinded Placebo Oral Suspension for Diabetes Trial/Canada

Blinded Placebo Oral Suspension for Diabetes Trial from Canada

This is a liquid placebo suspension in measured doses, identical in taste and appearance to the active drug, used in double-blinded Phase III clinical trials for diabetes medications. It falls under HTS 3006.93.60.00 as a blinded clinical trial kit in liquid form for oral intake, per Chapter 30 Note 6(e), excluding actual medicaments.

Duty Rate — Canada → United States

100%

Rate breakdown

9903.04.60100%Pharmaceuticals Annex IV: patented pharma articles — 100% floor rate

9903.05.860%Universal product exemption (U.S. note 52(b))

9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)

Calculate with your customs value Verify classification with AI

Import Tips

• Obtain FDA approval via Investigational New Drug (IND) application confirming recognized clinical trial status to justify 3006 classification

• Provide sponsor documentation showing product is a placebo or blinded kit in measured doses for oral intake, avoiding misclassification as food under Chapter 21

• Label clearly as 'Clinical Trial Material - Not for Sale' with stability data to prevent customs holds on shelf-life concerns